CCA
TPTX

Catalyst Capital Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Catalyst Capital Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-295
Closed -$11K – 450
2019
Q3 		$11K Hold
295
– – ﹤0.01% 340
2019
Q2 		$12K Buy
+295
New +$10.5K ﹤0.01% 306

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Catalyst Capital Advisors's TPTX Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2019, closing a stake of 295 shares — an estimated $11K sold.

Catalyst Capital Advisors first reported a position in TPTX in Q2 2019 and held it in 2 quarters. The position peaked at $12K in Q2 2019. 120 funds tracked by Wall St. Rank hold TPTX as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 295 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $11K.
  • Catalyst Capital Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Catalyst Capital Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $12K in Q2 2019.
  • 120 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.